XTLB
XTL Biopharmaceuticals
XTLB
XTLB
4 hedge funds and large institutions have $216K invested in XTL Biopharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
UBS Group
Zurich,
Switzerland
|
$108 |
| 2 |
2
BNP Paribas Financial Markets
Paris,
France
|
$269 |
Top Sellers
| 1 |
1
Morgan Stanley
New York
|
$36.4K |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $179K | 198,888 | – | – |
|
|
2
Morgan Stanley
New York
| $36.4K | 40,571 | -600 | -1% |
|
|
3
BNP Paribas Financial Markets
Paris,
France
| $269 | 300 | +100 | +50% |
|
|
4
UBS Group
Zurich,
Switzerland
| $108 | 120 | +120 | New |
|
|
CFGS
5
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|